Supporting Information

Polarity Control of DNA Adsorption Enabling Surface Functionalization of CuO Nanozyme for Targeted Tumor Therapy

Yingcai Meng¹, Yuan Chen¹, Jiaojiao Zhu¹, Yan Qi², Jinsong Ding¹, Wenhu Zhou^{1*}

 Xiangya School of Pharmaceutical Sciences, Central South University, Changsha, Hunan 410013, China.

2. Department of Pathology, Shihezi University School of Medicine & the First Affiliated Hospital to Shihezi University School of Medicine, Shihezi, Xinjiang, 832002, China.

*Email: zhouwenhuyaoji@163.com



Figure S1. The release kinetics of Cu ions from CuO NPs.



Figure S2. The adsorption of FAM-labeled 15-mer DNA homo-polymers (20 nM) by 50 μg/mL CuO NPs in HEPES buffer (10 mM, pH 7.6, 150 mM NaCl).



Figure S3. DNA desorption kinetics from CuO NPs surface in presence of 500 mM NaCl.



Figure S4. The ζ potential of CuO NPs, (TC)₁₂ DNA/CuO and di-DNA/CuO.



Figure S5. Colloidal stability of bare CuO NPs in water.



Figure S6. Cell viability of MDA-MB-231 cells after incubation with different Cu^{2+} concentrations for 24 h.



Figure S7. The cellular uptake of di-DNA/CuO by MDA-MB-231 cells without or with pretreatment of different concentrations of free adenosine. *P < 0.05, **P < 0.01.



Figure S8. Hemolysis test of CuO, $(TC)_{12}$ DNA/CuO and di-DNA/CuO at different concentrations. Negative control and positive control were 0.9% saline and Triton X-100,

respectively. All these formulations showed minimal hemolysis as compared to the positive control, demonstrating the biosafety of the nano-systems for intravenous injection.



Figure S9. Dynamic monitoring the body weight for 20 days with different treatments.



Figure S10. Representative H&E staining images of main organs (heart, liver, spleen, lung and kidney) after the treatments, scale bar = $50 \mu m$.